Authors: DEJONGE J HEIRMAN C DEVEERMAN M VANMEIRVENNE S DEMANET C BRISSINCK J THIELEMENS K

Citation: J. Dejonge et al., BISPECIFIC ANTIBODY TREATMENT OF MURINE B-CELL LYMPHOMA, Cancer immunology and immunotherapy, 45(3-4), 1997, pp. 162-165

Authors: BRISSINCK J RUSSELL SJ

Citation: J. Brissinck et Sj. Russell, VACCINE STRATEGIES IN NON-HODGKINS-LYMPHOMAS, Bailliere's clinical haematology, 9(4), 1996, pp. 799-817

Authors: HOLLIGER P BRISSINCK J WILLIAMS RL THIELEMANS K WINTER G

Citation: P. Holliger et al., SPECIFIC KILLING OF LYMPHOMA-CELLS BY CYTOTOXIC T-CELLS MEDIATED BY ABISPECIFIC DIABODY, Protein engineering, 9(3), 1996, pp. 299-305

Authors: DEMANET C BRISSINCK J DEJONGE J THIELEMANS K

Citation: C. Demanet et al., BISPECIFIC ANTIBODY-MEDIATED IMMUNOTHERAPY OF THE BCL(1) LYMPHOMA - INCREASED EFFICACY WITH MULTIPLE INJECTIONS AND CD28-INDUCED COSTIMULATION, Blood, 87(10), 1996, pp. 4390-4398

Authors: DEJONGE J BRISSINCK J HEIRMAN C DEMANET C LEO O MOSER M THIELEMANS K

Citation: J. Dejonge et al., PRODUCTION AND CHARACTERIZATION OF BISPECIFIC SINGLE-CHAIN ANTIBODY FRAGMENTS, Molecular immunology, 32(17-18), 1995, pp. 1405-1412

Authors: DEMANET C BRISSINCK J LEE O MOSER M THIELEMANS K

Citation: C. Demanet et al., ROLE OF T-CELL SUBSETS IN THE BISPECIFIC ANTIBODY (ANTIIDIOTYPE X ANTI-CD3) TREATMENT OF THE BCL(1) LYMPHOMA, Cancer research, 54(11), 1994, pp. 2973-2978